KH631

DRUG2 trials

Sponsors

Chengdu Origen Biotechnology Co., Ltd.

Conditions

Age-Related Macular Degeneration

Phase 1

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Active, not recruitingNCT05657301

Chengdu Origen Biotechnology Co., Ltd.Age-Related Macular Degeneration

Start: 2023-10-16End: 2027-09-30Target: 25Updated: 2025-12-31

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

RecruitingNCT05672121

Chengdu Origen Biotechnology Co., Ltd.Age-Related Macular Degeneration

Start: 2023-02-06End: 2026-12-28Target: 42Updated: 2024-11-27